Timerman D, McEnery-Stonelake M, Joyce C, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget. 2017;8(4):6873-6882.
To determine whether vitamin D deficiency and repletion are associated with melanoma outcome. Patients with 25-hydroxyvitamin D3 (25[OH]D3) <21 ng/mL were advised to take 50,000 IU vitamin D3 per week for 8 weeks and then continue with 4,000 IU per week.
Retrospective single-center study of medical records from January 2007 through June 2013.
Records from 252 individuals with a 25(OH)D3 level recorded within 1 year after histopathological diagnosis of melanoma were included in the study. Individual and melanoma characteristics such as age, sex, Breslow’s thickness, ulceration, stage, mitotic rate, and lactate dehydrogenase (LDH) levels were obtained from medical records. Subgroup analysis included 168 patients with a subsequent 25(OH)D3 level that had been recorded at any time (ie, patients with more than 1 vitamin D level in their records).
Study Parameters Assessed
Vitamin D deficiency status was based on current practice guidelines from the Endocrine Society. For comparison, the analysis included effects of changes in 25(OH)D3 levels on survival.
Primary Outcome Measures
Vitamin D levels, markers of melanoma growth (LDH levels, mitotic growth, ulceration, stage), and survival/death.
Patients who died were more likely to have vitamin D deficiency (<21 ng/mL; P=0.012), LDH>240 U/L (P<0.001), older age (>50 years; P=0.007), higher stage (P<0.001), ulceration (P=0.001), and higher mitotic rate (P=0.001) compared to those who were alive or lost to follow-up at the end of the study. Patients with vitamin D deficiency (<21 ng/mL) were more likely to have a higher stage of disease (P=0.01) as well as higher mortality (P=0.012). Patients with metastatic melanoma who were deficient and taking vitamin D but did not obtain ≥20 ng/dL increase in serum levels had a worse prognosis (hazard ratio [HR]: 4.68; 95% confidence interval [CI]: 1.05-20.88) than those who were vitamin D replete and had >20 ng/mL increase in vitamin D. Collectively, these results suggest that initial vitamin D deficiency and insufficient repletion is associated with a worse prognosis in patients with metastatic melanoma.
Melanoma diagnoses in the United States increased at a rate of 3.1% per year from 1992 to 2004.1 Lifetime risk of melanoma in the United States is 1 in 39 for Caucasian men and 1 in 58 for Caucasian women.2 The increased risk for this commonly fatal skin cancer has driven research in both prevention and treatment.
Much debate surrounds the relationship between vitamin D and cancer, including melanoma.3-5 This study confirms earlier studies that found lower serum 25(OH)D levels were associated with increased melanoma risk, greater Breslow thickness, and worse overall survival,6 and that 25(OH)D level during follow-up was an independent prognostic marker.7 The association of vitamin D and risk of melanoma, however, is confounded by other studies showing no association between vitamin D levels and mortality, and studies that show increased melanoma incidence in patients with high levels of vitamin D.8,9 Yet in this regard, it is important to consider that melanoma risk is related to repeated overexposure to ultraviolet B (UVB) radiation (blistering sunburns) rather than cumulative lifetime exposure.
Collectively, these results suggest that initial vitamin D deficiency and insufficient repletion is associated with a worse prognosis in patients with metastatic melanoma.
Given that patients with melanoma are counseled to avoid sun exposure and take supplemental vitamin D, this study provides an evidence basis for such a recommendation. One of these reviewers (Traub) has published a study providing evidence that a repletion strategy of 10,000 IU of vitamin D3 for 3 months is safe and effective.10
The authors of the study reviewed here suggest that since serum 25(OH)D has been associated with a robust immune response, it might be considered a marker of immune sufficiency in patients with metastatic melanoma. Similarly, UV radiation, in particular the UVB range, is known to be immunosuppressive to the skin. DNA damage induced by UVB is not only a carcinogen but also a major trigger of UV-induced immunosuppression.11
We were unable to verify the sources and dosage of vitamin D supplements taken by participants in the study. We also acknowledge that large prospective clinical trials of patients with melanoma receiving vitamin D supplementation are necessary to prove a causal relationship.
The main takeaway is that we should obtain 25(OH)D3 levels for all patients with melanoma, and for those who are deficient, supplement with vitamin D3 until repletion. We should maintain repletion with 2,000 to 4,000 IU daily. Use the same strategy for patients with a history of melanoma, to prevent recurrence.